Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

British Journal of Haematology

Volumn 156, Issue 5, 2012, Pages 619-625

  Sibon, David ^a,i   Cannas, Giovanna ^a   Baracco, Fiorenza ^a   Prebet, Thomas ^b   Vey, Norbert ^b   Banos, Anne ^c   Besson, Caroline ^d   Corm, Selim ^e   Blanc, Michel ^e   Slama, Bohrane ^f   Perrier, Hervé ^a   Fenaux, Pierre ^g   Wattel, Eric ^a,h  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c CENTRE HOSPITALIER DE LA CÔTE BASQUE   (France)

^d BICÊTRE HOSPITAL   (France)

^e CENTRE HOSPITALIER DE CHAMBÉRY   (France)

^f CENTRE HOSPITALIER D AVIGNON   (France)

^g AVICENNE HOSPITAL   (France)

^h CENTRE LÉON BÉRARD   (France)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Anaemia; Lenalidomide; Lower risk; Myelodysplastic syndrome

Indexed keywords

ANTIANEMIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER RELAPSE; CHROMOSOME DELETION 5; CHROMOSOME DELETION 5Q; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EDEMA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HUMAN; KARYOTYPING; MALE; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMATINICS; HUMANS; KARYOTYPE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RECURRENCE; THALIDOMIDE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84857033689     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08979.x     Document Type: Article

References (27)

1. Ades, L., Boehrer, S., Prebet, T., Beyne-Rauzy, O., Legros, L., Ravoet, C., Dreyfus, F., Stamatoullas, A., Chaury, M.P., Delaunay, J., Laurent, G., Vey, N., Burcheri, S., Mbida, R.M., Hoarau, N., Gardin, C. & Fenaux, P. (2009) Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood, 113, 3947-3952.
2. Balleari, E., Rossi, E., Clavio, M., Congiu, A., Gobbi, M., Grosso, M., Secondo, V., Spriano, M., Timitilli, S. & Ghio, R. (2006) Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Annals of Hematology, 85, 174-180.
3. Chang, D.H., Liu, N., Klimek, V., Hassoun, H., Mazumder, A., Nimer, S.D., Jagannath, S. & Dhodapkar, M.V. (2006) Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood, 108, 618-621.
4. Cheson, B.D., Bennett, J.M., Kantarjian, H., Pinto, A., Schiffer, C.A., Nimer, S.D., Lowenberg, B., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Wijermans, P.W., Gore, S. & Greenberg, P.L. (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood, 96, 3671-3674.
5. Cheson, B.D., Greenberg, P.L., Bennett, J.M., Lowenberg, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Gore, S.D., Schiffer, C.A. & Kantarjian, H. (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108, 419-425.
6. Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S.P., Richardson, P.G., Schlossman, R.L., Morgan, G.J., Muller, G.W., Stirling, D.I. & Anderson, K.C. (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98, 210-216.
7. Gohring, G., Giagounidis, A., Busche, G., Kreipe, H.H., Zimmermann, M., Hellstrom-Lindberg, E., Aul, C. & Schlegelberger, B. (2010) Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Annals of Hematology, 89, 365-374.
8. Greenberg, P.L. (2010) Current therapeutic approaches for patients with myelodysplastic syndromes. British Journal of Haematology, 150, 131-143.
9. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
10. Greenberg, P.L., Sun, Z., Miller, K.B., Bennett, J.M., Tallman, M.S., Dewald, G., Paietta, E., van der Jagt, R., Houston, J., Thomas, M.L., Cella, D. & Rowe, J.M. (2009) Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood, 114, 2393-2400.
11. Haslett, P.A., Corral, L.G., Albert, M. & Kaplan, G. (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. The Journal of Experimental Medicine, 187, 1885-1892.
12. Itzykson, R., Ayari, S., Vassilief, D., Berger, E., Slama, B., Vey, N., Suarez, F., Beyne-Rauzy, O., Guerci, A., Cheze, S., Thomas, X., Stamatoullas, A., Gardembas, M., Bauduer, F., Kolb, A., Chaury, M.C., Legros, L., Damaj, G., Chermat, F., Dreyfus, F., Fenaux, P. & Ades, L. (2009) Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases. Leukemia, 23, 673-678.
13. Jadersten, M., Montgomery, S.M., Dybedal, I., Porwit-MacDonald, A. & Hellstrom-Lindberg, E. (2005) Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood, 106, 803-811.
14. Jadersten, M., Malcovati, L., Dybedal, I., Della Porta, M.G., Invernizzi, R., Montgomery, S.M., Pascutto, C., Porwit, A., Cazzola, M. & Hellstrom-Lindberg, E. (2008) Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. Journal of Clinical Oncology, 26, 3607-3613.
15. Kaplan, E. & Meier, P. (1958) Non parametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
16. List, A.F. (2007) Lenalidomide - the phoenix rises. New England Journal of Medicine, 357, 2183-2186.
17. List, A., Kurtin, S., Roe, D.J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R. & Zeldis, J.B. (2005) Efficacy of lenalidomide in myelodysplastic syndromes. New England Journal of Medicine, 352, 549-557.
18. List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., Reeder, C., Wride, K., Patin, J., Schmidt, M., Zeldis, J. & Knight, R. (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. New England Journal of Medicine, 355, 1456-1465.
19. Moyo, V., Lefebvre, P., Duh, M.S., Yektashenas, B. & Mundle, S. (2008) Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Annals of Hematology, 87, 527-536.
20. Mundle, S.D. (2006) Advances in erythropoietic growth factor therapy for myelodysplastic syndromes. Expert Opinion on Biological Therapy, 6, 1099-1104.
21. Mundle, S.D. & Raza, A. (2006) Treatment of myelodysplastic syndromes with exogenous erythropoietin: a new therapeutic paradigm. Leukemia, 20, 1481-1483.
22. Musto, P. (2005) Revisiting the use of recombinant erythropoietin in myelodysplastic syndromes. Clinical Lymphoma, 6, 52-55.
23. Musto, P., Villani, O., Martorelli, M.C., Pietrantuono, G., Guariglia, R., Mansueto, G., D'Auria, F., Grieco, V., Bianchino, G., Sparano, A., Zonno, A., Lerose, R., Sanpaolo, G. & Falcone, A. (2010) Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes. Leukemia Research, 34, 981-985.
24. Raza, A., Reeves, J.A., Feldman, E.J., Dewald, G.W., Bennett, J.M., Deeg, H.J., Dreisbach, L., Schiffer, C.A., Stone, R.M., Greenberg, P.L., Curtin, P.T., Klimek, V.M., Shammo, J.M., Thomas, D., Knight, R.D., Schmidt, M., Wride, K., Zeldis, J.B. & List, A.F. (2008) Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood, 111, 86-93.
25. Ross, S.D., Allen, I.E., Probst, C.A., Sercus, B., Crean, S.M. & Ranganathan, G. (2007) Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist, 12, 1264-1273.
26. Sekeres, M.A. & List, A. (2006) Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?Current Hematologic Malignancy Reports, 1, 16-19.
27. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellstrom-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-951.